Aurora Cannabis Inc.

NASDAQ:ACB

Drug Manufacturers - Specialty & Generic

Healthcare
$4.40 +0.51%

+$0.02 today

Market cap
$289.28M
Beta
1.34
P/E (TTM)
-3.2
EPS (TTM)
-$1.31
52W Low $2.73High $6.67

Volume 0.92M

Average 1.00M

ACB Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Aurora Cannabis Inc.NASDAQ: ACB

Cost of Revenue · Q4 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q4 FY2026 cost of revenue of CA$19.94M fell 71.0% year over year, behind the -13.4% change in trailing-twelve-month cost of revenue. Sequentially, it fell 58.1% from the prior quarter. Over 3 fiscal years it compounded at +13.4% a year.

Context

  • Cost of revenue amounted to 94.8% of revenue in FY2026, up 49.4 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -71.0% toward the trailing-twelve-month pace of -13.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$19.94M-58.1% QoQ
Last fiscal yearMar 2026
CA$304.67M+95.7% YoY
LTMMar 2026
CA$134.79M-13.4% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-71.0%——
1 year+95.7%——
3-year CAGR+13.4%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

CAD · from the income statement

Latest · FY2026
304.67M CAD
Year-over-year change
+95.7%
4-year CAGR
+11.1%

Cost of Revenue vs competitors

How ACB compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -13.4% is the 6th highest of 9, against a peer median of +1.2%.
  • Cost of revenue amounts to 43.4% of revenue for ACB, versus a peer median of 65.5%.
ACB Competitors
Cost of Revenue for ACB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HITIHigh Tide Inc.LTM Apr 2026CA$553.94M CAD+35.7%+19.8%82.5%
CGCCanopy Growth CorporationLTM Mar 2026CA$234.68M CAD+23.9%-0.9%75.1%
OGIOrganigram Global Inc.LTM Mar 2026CA$176.48M CAD+35.1%—64.4%
ACBAurora Cannabis Inc.LTM Mar 2026CA$134.79M CAD-13.4%+13.4%43.4%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$93.03M USD—+7.0%68.8%
EDITEditas Medicine, Inc.LTM Mar 2026$36.44M USD-53.4%—94.2%
LFMDLifeMD, Inc.LTM Mar 2026$30.96M USD+10.1%+28.2%14.1%
TKNOAlpha Teknova, Inc.LTM Mar 2026$27.87M USD-7.8%+4.2%66.7%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$1.98M USD-86.0%-44.1%23.7%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$1.39M USD-97.6%—0.4%
BIOABioAge Labs, Inc.LTM Mar 2026$63K USD——0.6%
Peer median (excluding ACB) —+1.2%+5.6%65.5%

Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2022
Jun 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue221.34M223.8M270.28M343.29M321.42M
Cost of Revenue200.11M209.02M138.82M155.69M304.67M
Gross Profit21.23M14.78M131.46M187.61M16.75M
Gross Margin9.6%6.6%48.6%54.6%5.2%
Research & Development10.39M5.77M3.57M3.68M6.01M
Selling, General & Admin188.99M170.48M156.88M166.47M173.95M
Operating Expenses252.67M221.98M177.91M182.66M179.96M
Depreciation & Amortization93.66M52.59M33.07M22.55M14.23M
EBITDA(1.55B)(135M)(12.34M)51.35M(148.99M)
EBITDA Margin-702.4%-60.3%-4.6%15.0%-46.4%
Operating Income(231.45M)(207.19M)(46.45M)4.95M(163.21M)
Operating Margin-104.6%-92.6%-17.2%1.4%-50.8%
Interest Income4.51M19M12.81M11.51M5.86M
Interest Expense71.81M39.46M14.19M8.42M1.81M
Other Income / Expenses(1.49B)(576.51M)(13.15M)15.43M106.54M
Income Before Tax(1.72B)(783.7M)(59.6M)20.38M(56.67M)
Pre-Tax Margin-777.1%-350.2%-22.1%5.9%-17.6%
Income Tax Expense(2.14M)16.55M(554K)4.62M2.1M
Net Income(1.72B)(816.63M)(69.33M)1.59M(122.07M)
Net Margin-776.0%-364.9%-25.6%0.5%-38.0%
EPS (Basic)(79.92)(8.17)(1.28)0.03(2.15)
EPS (Diluted)(79.92)(8.17)(1.28)0.03(2.15)
Weighted Avg Shares21.49M32.27M51.26M54.88M56.71M
Weighted Avg Shares (Diluted)21.49M32.27M51.26M55.75M56.71M

Aurora Cannabis Inc.

NASDAQ:ACB

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.